Skip to Content

WATSON 3209 (Rivastigmine Tartrate 3 mg)

Pill with imprint WATSON 3209 is Yellow, Capsule-shape and has been identified as Rivastigmine Tartrate 3 mg. It is supplied by Watson Pharmaceuticals.

Rivastigmine is used in the treatment of alzheimer's disease; parkinson's disease and belongs to the drug class cholinesterase inhibitors. There is no proven risk in humans during pregnancy. Rivastigmine 3 mg is not a controlled substance under the Controlled Substances Act (CSA).

Images for WATSON 3209

Rivastigmine Tartrate

Imprint
WATSON 3209
Strength
3 mg
Color
Yellow
Size
18.00 mm
Shape
Capsule-shape
Availability
Prescription only
Drug Class
Cholinesterase inhibitors
Pregnancy Category
B - No proven risk in humans
CSA Schedule
Not a controlled drug
Labeler / Supplier
Watson Pharmaceuticals
Inactive Ingredients
silicon dioxide, magnesium stearate, microcrystalline cellulose, gelatin, titanium dioxide, ferric oxide yellow, D&C Yellow No. 10, FD&C Blue No. 1, FD&C Blue No. 2, indigotindisulfonate sodium, FD&C Red No. 40, shellac, propylene glycol

Note: Inactive ingredients may vary.

Labelers / Repackagers

NDC CodeLabeler / Repackager
00591-3209 Watson Pharmaceuticals, Inc.
63739-0577 McKesson Packaging Services

Get help with Imprint Code FAQs.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.